NCT03319290 is a clinical trial of BRCA1 and BRCA2 in Hereditary Cancer, sponsored by Data Collection Analysis Business Management.

Who is sponsoring NCT03319290?

NCT03319290 is sponsored by Data Collection Analysis Business Management.

What drugs are being tested in NCT03319290?

Interventions in NCT03319290: BRCA1 and BRCA2.

What condition does NCT03319290 study?

NCT03319290 studies Hereditary Cancer.

Is NCT03319290 still recruiting?

NCT03319290 is currently status unknown. Last updated 23 January 2019.

Last reviewed 2019-01-23 · How we verify

NCT03319290

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Increase Surveillance for Breast and Ovarian Cancers, Also to Determine Targeted Risk-reducing and Preventative Strategies

Status unknown Last updated 23 January 2019

What this trial tests

trial testing BRCA1 and BRCA2 in Hereditary Cancer in 2,000 participants. Status unknown.

Timeline

17 October 2017

Primary endpoint
1 October 2020

17 October 2020

Quick facts

Lead sponsor	Data Collection Analysis Business Management
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	17 October 2017
Primary completion	1 October 2020
Estimated completion	17 October 2020
Sites	1 location across United States

Drugs / interventions tested

BRCA1 and BRCA2

Conditions studied

Hereditary Cancer — all drugs for Hereditary Cancer →

Sponsor

Data Collection Analysis Business Management

Who can join

Adults 18 to 65, any sex, with Hereditary Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational study is to increase surveillance for breast and ovarian cancers, also to determine targeted risk-reducing and preventative strategies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hereditary Cancer

Currently open trials in the same condition.

NCT06157801 — Evaluation of Hereditary Cancer Educational Videos · active not recruiting
NCT06708429 — Lynch Syndrome X-Talk of Enteral Mucosa With Immune System · recruiting

Other Data Collection Analysis Business Management trials

Trials by the same sponsor.

NCT03768011 — Subjective Observational Study of Patients Using Transdermal Cream Medication And/Or Transdermal Patches With Or Without · unknown
NCT03781024 — A Subjective Observational Study of Patients Using Medicated Footbath/Footwash Treatment in Podiatry Care · unknown
NCT03322254 — How Respiratory Pathogens Panel Results Affect Patients' Plan of Care · unknown
NCT03322176 — Healthcare Decisions Post-Testing, Risk-reducing and Preventative Strategies Using LYNCH Genetic Testing Reducing, and P · unknown
NCT03322241 — Increase Surveillance for Wellness Decisions, Also to Determine Targeted Risk-reducing and Preventative Strategies · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03319290 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Data Collection Analysis Business Management
Last refreshed: 23 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03319290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing